George Bakris to Spironolactone
This is a "connection" page, showing publications George Bakris has written about Spironolactone.
Connection Strength
2.499
-
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail. 2017 06; 19(6):792-799.
Score: 0.582
-
Spironolactone for resistant hypertension--hard to resist? Lancet. 2015 Nov 21; 386(10008):2032-2034.
Score: 0.536
-
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30(5):418-24.
Score: 0.353
-
Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Curr Diab Rep. 2022 05; 22(5):213-218.
Score: 0.212
-
Evolution of Patiromer Use: a Review. Curr Cardiol Rep. 2020 07 09; 22(9):94.
Score: 0.187
-
Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. Hypertension. 2020 07; 76(1):144-149.
Score: 0.186
-
Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017 09; 26(5):368-374.
Score: 0.154
-
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014 Jan; 7(1):51-8.
Score: 0.118
-
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008 Oct 14; 118(16):1643-50.
Score: 0.083
-
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 01 07; 42(2):152-161.
Score: 0.048
-
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail. 2018 08; 5(4):592-602.
Score: 0.040